By way of learning-by-doing, we'll look at ROE to gain a better understanding of Zoetis Inc. (NYSE:ZTS). Return on equity or ROE is a key measure used to assess how efficiently a company's ...

The firm decreased its portfolio allocation in ZTS by 30.95% over the last quarter. Alliancebernstein holds 15,389K shares representing 3.41% ownership of the company. In its prior filing ...

PARSIPPANY, N.J., December 12, 2024--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic ...

Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation. For those of you who don't know me, I'm Glen Santangelo. I'm the analyst at ...

ZTS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. ZTS has a Growth Style Score of B, forecasting year-over-year ...

Leerink Partners has recently initiated Zoetis Inc (ZTS) stock to Outperform rating, as announced on December 2, 2024, according to Finviz. Earlier, on July 25, 2024, BTIG Research had initiated the ...